Estradiol/norethisterone transdermal - Noven
Alternative Names: Aliatis®; CombiPatch; E2/NETA patch - Noven; Estalis; Estradiol/norethisterone transdermal - Novartis; Estragest; RPR-106522Latest Information Update: 25 Sep 2021
At a glance
- Originator Noven Pharmaceuticals
- Developer ASKA Pharmaceutical; Noven Pharmaceuticals; Novogyne Pharmaceuticals; Yakult Honsha
- Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 31 Jan 2019 Chemical structure information added
- 27 Aug 2009 Noven Pharmaceuticals has been acquired by Hisamitsu Pharmaceutical
- 25 May 2006 This compound is still in active development